Jason Flamiatos
Payments from drug & device makers
What this record shows
28 manufacturers reported payments, led by Boston Scientific at 53.9% of the total.
Across 93 payments — averaging $113.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$6K
- Intuitive Surgical$2K
- Procept Biorobotics Corporation$731
- Agiliti Surgical, Inc.$701
- Dornier Medtech America, Inc$565
- Axonics, Inc.$148
- plus $972 from 22 others
What the payments were for
- Travel & lodging$5,94956%
- Food & beverage$4,61044%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 29 | $5,688 |
| Intuitive Surgical | 3 | $1,755 |
| Procept Biorobotics Corporation | 9 | $731 |
| Agiliti Surgical, Inc. | 8 | $701 |
| Dornier Medtech America, Inc | 2 | $565 |
| Axonics, Inc. | 2 | $148 |
| Bayer | 5 | $107 |
| Profound Medical Corp. | 1 | $98 |
| C. R. Bard, Inc. & Subsidiaries | 4 | $94 |
| Sumitomo Pharma America, Inc. | 4 | $75 |
| Olympus America Inc. | 1 | $68 |
| Progenics Pharmaceuticals, Inc. | 3 | $67 |
| Immunitybio, Inc. | 3 | $57 |
| Calyxo, Inc. | 1 | $49 |
| Johnson & Johnson | 2 | $42 |
| Astellas Pharma US Inc | 2 | $38 |
| Urogen Pharma, Inc. | 1 | $34 |
| Accord Healthcare, Inc. | 2 | $33 |
| Coloplast | 2 | $33 |
| Endo USA, Inc. | 1 | $27 |
| Medtronic | 1 | $22 |
| Sun Pharmaceutical Industries Inc. | 1 | $22 |
| Laborie Medical Technologies Corp. | 1 | $22 |
| Ambu Inc. | 1 | $20 |
| Tolmar, Inc. | 1 | $19 |
| Rochester Medical Corporation | 1 | $16 |
| Pfizer | 1 | $15 |
| AbbVie | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,558 in reported general payments places this provider in the 85th percentile of 153 urology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NubeqaDarolutamide | 27 | $363,364 |
| XtandiEnzalutamide | 16 | $157,541 |
| OrgovyxRelugolix | 49 | $129,755 |
| MyrbetriqMirabegron | 31 | $46,277 |
| Abiraterone Acetate | 23 | $43,174 |
| GemtesaVibegron | 24 | $28,964 |
| Tamsulosin Hcl | 294 | $3,874 |
| Tadalafil | 32 | $1,750 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 87 | $956 |
| Bicalutamide | 29 | $889 |
| Solifenacin Succinate | 13 | $586 |
| Finasteride | 38 | $476 |
| Megestrol Acetate | 13 | $359 |
| Ciprofloxacin Hcl | 108 | $326 |
| Levofloxacin | 25 | $321 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerNubeqa | $107 | $363,36427 claims |
| Astellas Pharma US IncXtandi, Myrbetriq | $38 | $203,81847 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $75 | $158,71973 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 153 urology providers in Oregon.
Other urology in Bend
- Matt AshleyBend$212K
- Willie UnderwoodBend$11K
- Andrew NeebBend$9K
- Hagop SarkissianBend$4K
- Michael LavelleBend$3K
- Daniel WillisBend$3K
- Bryan MehlhaffSpringfield$1M
- Lance MarrPortland$323K
- da David JiangPortland$65K
- Kim ThaiMedford$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.